|

Randomization of Single vs Multiple Arterial Grafts

RECRUITINGN/ASponsored by Weill Medical College of Cornell University
Actively Recruiting
PhaseN/A
SponsorWeill Medical College of Cornell University
Started2018-01-07
Est. completion2027-06-30
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
Locations11 sites

Summary

The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival. Prospective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Primary isolated CABG patients with disease of the left main coronary artery and/or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.

Exclusion Criteria:

* Age \> 70 years
* Single graft
* Emergency operation
* Evolving myocardial infarction within 48 hours of surgery
* Left ventricular ejection fraction of \< 35%
* Any concomitant cardiac or non-cardiac procedure
* Previous cardiac surgery
* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years.
* Inability to use the saphenous vein or to use both radial and right internal thoracic arteries
* Anticipated need for coronary thrombo-endarterectomy
* Planned hybrid revascularization

Conditions3

Coronary Artery DiseaseHeart DiseaseHeart Diseases

Locations11 sites

University of Colorado
Boulder, Colorado, 80309
Jessica Rove
Baystate Health
Springfield, Massachusetts, 01109
Nebraska Heart Hospital
Lincoln, Nebraska, 68526
Thomas Kleisli
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Aleem Siddique
NewYork-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Sandhya Balaram, MD

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.